These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 14619908)

  • 1. Reorienting the course of medicines policy: actions are bearing fruit.
    Prescrire Int; 2003 Oct; 12(67):192-4. PubMed ID: 14619908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The advertising of medicinal products to the public in Poland--legislative, ethical, health and social concerns].
    Cianciara D
    Przegl Epidemiol; 2004; 58(3):555-63. PubMed ID: 15730020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct-to-consumer advertising of prescription drugs: European Commission persists in putting industry's interests first.
    Prescrire Int; 2013 Jan; 22(134):24-5, 27. PubMed ID: 23373084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Legislative and non-legislative regulations concerning Rx drug advertisement in the European Union and the United States--comparative analysis.
    Czerw A; Religioni U
    Acta Pol Pharm; 2012; 69(4):779-87. PubMed ID: 22876622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of direct-to-consumer advertising.
    Navarro RP
    Manag Care Interface; 1998 Nov; 11(11):79-80, 82. PubMed ID: 10187419
    [No Abstract]   [Full Text] [Related]  

  • 7. Europe reconsidering DTCA.
    Meek C
    CMAJ; 2007 May; 176(10):1405. PubMed ID: 17485687
    [No Abstract]   [Full Text] [Related]  

  • 8. Paternalistic or protective? Freedom of expression and direct-to-consumer drug advertising policy in Canada.
    Gold JL
    Health Law Rev; 2003; 11(2):30-6. PubMed ID: 15706698
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmaceuticals and medical devices: business practices. End-of-year issue brief.
    Jones TM
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-58. PubMed ID: 20213918
    [No Abstract]   [Full Text] [Related]  

  • 10. The new drug marketing: a consumer protection perspective.
    Woodward D
    Food Drug Law J; 1996; 51(4):637-50. PubMed ID: 11797733
    [No Abstract]   [Full Text] [Related]  

  • 11. Medicine goes Madison Avenue: an evaluation of the effect of direct-to-consumer pharmaceutical advertising on the learned intermediary doctrine.
    Allen MC
    Spec Law Dig Health Care Law; 1998 Dec; (236):9-29. PubMed ID: 10187553
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmaceuticals and medical devices: business practices. End-of-year issue brief.
    Jones TM
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-32. PubMed ID: 18345554
    [No Abstract]   [Full Text] [Related]  

  • 13. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
    Alván G
    Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
    [No Abstract]   [Full Text] [Related]  

  • 14. Restrictions on the conduct of advertising of medicinal products in Poland and their violations.
    Czerw A; Marek EM
    Acta Pol Pharm; 2013; 70(4):769-76. PubMed ID: 23923402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical regulation in the European Community: barriers to single market integration.
    Orzack LH; Kaitin KI; Lasagna L
    J Health Polit Policy Law; 1992; 17(4):847-68. PubMed ID: 1299692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EU health ministers reject proposal for limited direct to consumer advertising.
    Watson R
    BMJ; 2003 Jun; 326(7402):1284. PubMed ID: 12805139
    [No Abstract]   [Full Text] [Related]  

  • 17. Experimenting with direct-to-consumer advertising.
    Lancet; 2000 Aug; 356(9230):607. PubMed ID: 10968426
    [No Abstract]   [Full Text] [Related]  

  • 18. Supreme Court decision may have major impact on drug industry.
    Spurgeon D
    CMAJ; 1993 Feb; 148(4):629-31. PubMed ID: 8431828
    [No Abstract]   [Full Text] [Related]  

  • 19. [Generic drug policy implementation in Brazil].
    Dias CR; Romano-Lieber NS
    Cad Saude Publica; 2006 Aug; 22(8):1661-9. PubMed ID: 16832537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bitter pill for plaintiffs: obstacles to market theories of causation in prescription drug consumer fraud cases.
    Arden JD; Brensilver PC
    Food Drug Law J; 2006; 61(3):539-46. PubMed ID: 17001790
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.